Last reviewed · How we verify

Glucosamine sulfate + chondroitin sulfate - MANTECORP

Mantecorp Industria Quimica e Farmaceutica Ltd. · Phase 3 active Small molecule

Glucosamine sulfate + chondroitin sulfate - MANTECORP is a Symptomatic slow-acting drug in osteoarthritis (SYSADOA) Small molecule drug developed by Mantecorp Industria Quimica e Farmaceutica Ltd.. It is currently in Phase 3 development for Osteoarthritis (symptomatic treatment and disease modification).

Glucosamine sulfate and chondroitin sulfate work together to provide substrates for cartilage matrix synthesis and reduce cartilage degradation in osteoarthritis.

Glucosamine sulfate and chondroitin sulfate work together to provide substrates for cartilage matrix synthesis and reduce cartilage degradation in osteoarthritis. Used for Osteoarthritis (symptomatic treatment and disease modification).

At a glance

Generic nameGlucosamine sulfate + chondroitin sulfate - MANTECORP
SponsorMantecorp Industria Quimica e Farmaceutica Ltd.
Drug classSymptomatic slow-acting drug in osteoarthritis (SYSADOA)
ModalitySmall molecule
Therapeutic areaRheumatology / Orthopedics
PhasePhase 3

Mechanism of action

Glucosamine sulfate serves as a precursor for glycosaminoglycan synthesis, supporting cartilage matrix formation and potentially slowing cartilage breakdown. Chondroitin sulfate is a major component of cartilage extracellular matrix that helps retain water and resist compression, while also inhibiting enzymes that degrade cartilage. Together, these agents aim to modify disease progression in osteoarthritis by supporting cartilage structure and function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glucosamine sulfate + chondroitin sulfate - MANTECORP

What is Glucosamine sulfate + chondroitin sulfate - MANTECORP?

Glucosamine sulfate + chondroitin sulfate - MANTECORP is a Symptomatic slow-acting drug in osteoarthritis (SYSADOA) drug developed by Mantecorp Industria Quimica e Farmaceutica Ltd., indicated for Osteoarthritis (symptomatic treatment and disease modification).

How does Glucosamine sulfate + chondroitin sulfate - MANTECORP work?

Glucosamine sulfate and chondroitin sulfate work together to provide substrates for cartilage matrix synthesis and reduce cartilage degradation in osteoarthritis.

What is Glucosamine sulfate + chondroitin sulfate - MANTECORP used for?

Glucosamine sulfate + chondroitin sulfate - MANTECORP is indicated for Osteoarthritis (symptomatic treatment and disease modification).

Who makes Glucosamine sulfate + chondroitin sulfate - MANTECORP?

Glucosamine sulfate + chondroitin sulfate - MANTECORP is developed by Mantecorp Industria Quimica e Farmaceutica Ltd. (see full Mantecorp Industria Quimica e Farmaceutica Ltd. pipeline at /company/mantecorp-industria-quimica-e-farmaceutica-ltd).

What drug class is Glucosamine sulfate + chondroitin sulfate - MANTECORP in?

Glucosamine sulfate + chondroitin sulfate - MANTECORP belongs to the Symptomatic slow-acting drug in osteoarthritis (SYSADOA) class. See all Symptomatic slow-acting drug in osteoarthritis (SYSADOA) drugs at /class/symptomatic-slow-acting-drug-in-osteoarthritis-sysadoa.

What development phase is Glucosamine sulfate + chondroitin sulfate - MANTECORP in?

Glucosamine sulfate + chondroitin sulfate - MANTECORP is in Phase 3.

What are the side effects of Glucosamine sulfate + chondroitin sulfate - MANTECORP?

Common side effects of Glucosamine sulfate + chondroitin sulfate - MANTECORP include Gastrointestinal disturbances (nausea, dyspepsia, diarrhea), Headache, Rash.

Related